A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with...

... temozolomide in patients with recurrent glioblastoma.

BACKGROUND: Preclinical data suggest some cannabinoids may exert antitumour effects against glioblastoma (GBM). Safety and preliminary efficacy of nabiximols oromucosal cannabinoid spray plus dose-intense temozolomide (DIT) was evaluated in patients with first recurrence of GBM.

https://www.nature.com/articles/s41416-021-01259-3.pdf

Source: British Journal of Cancer via nature.com